Navigation Links
Cold winters freezing out breast cancer treatment

LONDON, ON For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer. Currently, tamoxifen is used in a one-size-fits-all approach where the same dose is prescribed for every patient. New research at Lawson Health Research Institute has found that in addition to patient-specific genetic factors, lack of exposure to vitamin D during the long winter months affects the body's ability to metabolize the drug.

The findings, which have been reported in the journal Breast Cancer Research and Treatment, are the first to identify this seasonal effect. Dr. Richard Kim, who is a physician at London Health Sciences Centre (LHSC) and holds the Wolfe Medical Research Chair in Pharmacogenomics at Western University, reports that during the winter months nearly 30 percent of patients are at risk for less than optimal level of the active form of tamoxifen, called endoxifen, and therefore may not benefit as much from the therapy.

In the liver, tamoxifen is converted to the active form of the drug called endoxifen by a protein called CYP2D6. "We know that endoxifen is nearly 100 times more potent against the estrogen receptor relative to tamoxifen," says Dr. Kim. "Our research has shown that patients with normal CYP2D6 activity can easily convert tamoxifen to endoxifen, whereas patients with no CYP2D6 activity have a significantly limited ability to convert tamoxifen to endoxifen."

In addition to the seasonal effect, Dr. Kim found that the simultaneous use of a common antidepressant can also substantially lower the body's ability to metabolize endoxifen levels. "Patients who are either partly or completely deficient in CYP2D6 and who are prescribed the SSRI class of antidepressants are at major risk for subtherapeutic endoxifen levels," says Dr. Kim.

With nearly 10 percent of the population completely lacking CYP2D6 enzymatic activity, these findings have important clinical applications. "Our most recent findings are important additions to the pool of data we already have on tamoxifen therapy," says Dr. Kim. "These new clinical and genetic markers can aid physicians to better identify patients who will benefit from tamoxifen, as well as those patients at risk for suboptimal benefit."


Contact: Robert DeLaet
519-685-8500 x75616
Lawson Health Research Institute

Related biology news :

1. Duck-billed dinosaurs endured long, dark polar winters
2. Extreme winters impact fish negatively
3. Freezing nerves knocks pain out cold
4. Protein jailbreak helps breast cancer cells live
5. Breast cancer risk gene discovery fast tracked by new technology
6. A new breast cancer susceptibility gene
7. Mechanism found connecting metastatic breast cancer and arthritis
8. Detecting breast cancers fingerprint in a droplet of blood
9. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
10. High levels of TRAIL protein in breast milk might contribute to anticancer activity
11. Fourth IMPAKT Breast Cancer Conference
Post Your Comments:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... ... Supplyframe, the Industry Network for electronics hardware design and ... in Pasadena, Calif., the Design Lab’s mission is to bring together inventors and ... brought to market. , The Design Lab is Supplyframe’s physical representation of one ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology: